Bio-Gate Valuation Multiples

Bio-Gate Overview

About Bio-Gate

Bio-Gate AG is a Germany based medical technology company. The company employs silver technology to endow materials and products with antimicrobial properties. It is focused on the medical technology products portfolio. In addition, its technologies are also used to refine cosmetics, consumer goods, and industrial products. The products of the company are plasma-coating, additives, textile solutions, spray, masterbatches, and others. The organization uses two different technologies; first, silver particles are incorporated into cosmetics, paints, veneers or plastics, and second involve coating final products like implants or wound dressings with a silver-containing functional layer.

Founded

2005

HQ

Employees

27

Website

biogate.de

Sectors

Medical Devices

Financials (LTM)

Revenue: $9M

EBITDA: ($737K)

EV

$6M

Valuation Multiples

Multiples.vc

Start free trial

Bio-Gate Financials

Bio-Gate reported last 12-month revenue of $9M and negative EBITDA of ($737K).

In the same LTM period, Bio-Gate generated ($737K) in EBITDA losses and had net loss of ($1M).

Bio-Gate P&L

In the most recent fiscal year, Bio-Gate reported revenue of $8M and EBITDA of ($2M).

Bio-Gate expects next 12-month revenue of XXX and NTM EBITDA of XXX

Bio-Gate Stock Performance

Bio-Gate has current market cap of $7M, and enterprise value of $6M.

Bio-Gate's stock price is $0.71.

Bio-Gate Valuation Multiples

Bio-Gate trades at 0.7x EV/Revenue multiple, and (8.1x) EV/EBITDA.

Bio-Gate Financial Valuation Multiples

As of April 20, 2026, Bio-Gate has market cap of $7M and EV of $6M.

Equity research analysts estimate Bio-Gate's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Bio-Gate has a P/E ratio of (5.9x).

Bio-Gate Margins & Growth Rates

Bio-Gate's revenue in the last 12 month grew by 9%.

Bio-Gate's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.3M for the same period.

Bio-Gate's rule of 40 is 8% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Bio-Gate's rule of X is 21% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Bio-Gate Public Comps

See public comps and valuation multiples for other Medical Devices comps.

Bio-Gate M&A Activity

Bio-Gate acquired XXX companies to date.

Last acquisition by Bio-Gate was on XXXXXXXX, XXXXX. Bio-Gate acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Bio-Gate Investment Activity

Bio-Gate invested in XXX companies to date.

Bio-Gate made its latest investment on XXXXXXXX, XXXXX. Bio-Gate invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).